Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Gastrointestinal Market Research

Gastrointestinal Testing Panels Market (Pathogen Type: Viruses, Bacteria, and Parasite; Type: Syndromic Full, Multiplex Panel, and Low Plex Panel; and End-user: Hospitals, Diagnostic Laboratories, Point-of-Care, and Others) - Europe and Middle East & Afri

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 250 Pages Transparency Market Research Pvt. Ltd. January, 2022 TNPR17063802
Best Price Guarantee
Price from $5,795
Length 250 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date January, 2022
SKU TNPR17063802

Gastrointestinal Testing Panels Market (Pathogen Type: Viruses, Bacteria, and Parasite; Type: Syndromic Full, Multiplex Panel, and Low Plex Panel; and End-user: Hospitals, Diagnostic Laboratories, Point-of-Care, and Others) - Europe and Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Europe and Middle East & Africa Gastrointestinal Testing Panels Market – Scope of Report
The latest study collated and published by Transparency Market Research (TMR) analyzes the historical and present-day scenario of the gastrointestinal testing panels market in EMEA to accurately gauge its growth potential. The study presents detailed information about important growth factors, restraints, and key trends that are creating the landscape for growth of the gastrointestinal testing panels market in EMEA in order to identify opportunities for stakeholders. The report also provides insightful information about how the gastrointestinal testing panels market in EMEA would expand during the forecast period of 2021 to 2031.

The report offers intricate dynamics about different aspects of the gastrointestinal testing panels market in EMEA, which aids companies operating in the market in making strategic decisions. TMR’s study also elaborates on the significant changes that are anticipated to configure growth of the gastrointestinal testing panels market in EMEA during the forecast period. It also includes key indicator assessment that highlights growth prospects for the gastrointestinal testing panels market in EMEA and estimates statistics related to the market in terms of value (US$ Mn).

This study covers detailed segmentation of the gastrointestinal testing panels market in EMEA, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the gastrointestinal testing panels market in EMEA, wherein various development, expansion, and winning strategies practiced by these players have been presented in detail.

Key Questions Answered in TMR’s Report on Europe and Middle East & Africa Gastrointestinal Testing Panels Market
The report provides detailed information about the gastrointestinal testing panels market in EMEA based on comprehensive research on various factors that are playing a key role in accelerating the growth of the market. Information mentioned in the report answers path-breaking questions for companies that are currently operating in the gastrointestinal testing panels market in EMEA and are looking for innovative methods to create a unique benchmark in the market in order to help them design successful strategies and make target-driven decisions.

Which segment of the gastrointestinal testing panels market in EMEA will emerge as a major revenue generator during the forecast period?
How are key market players earning revenue in the gastrointestinal testing panels market in EMEA?
What will be the Y-o-Y growth trend of the gastrointestinal testing panels market in EMEA between 2021 and 2031?
What are the winning imperatives of leading players operating in the gastrointestinal testing panels market in EMEA?
Research Methodology – Europe and Middle East & Africa Gastrointestinal Testing Panels Market
The research methodology adopted by analysts for compiling the report on the gastrointestinal testing panels market in EMEA is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts of the gastrointestinal testing panels market in EMEA.

During the primary research phase, analysts have interviewed market stakeholders, investors, brand managers, vice presidents, and sales & marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the gastrointestinal testing panels market in EMEA.

For secondary research, analysts have scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the gastrointestinal testing panels market in EMEA.


1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe and Middle East & Africa Gastrointestinal Testing Panels Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe and Middle East & Africa Gastrointestinal Testing Panels Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Gastrointestinal Disorders: Overview
5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Europe and Middle East & Africa Gastrointestinal Testing Panels Market Analysis and Forecast, by Pathogen Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Pathogen Type, 2017–2031
6.3.1. Viruses
6.3.2. Bacteria
6.3.3. Parasites
7. Europe and Middle East & Africa Gastrointestinal Testing Panels Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2017–2031
7.3.1. Syndromic Full Multiplex Panel
7.3.2. Low Plex Panel
7.4. Market Attractiveness Analysis, by Type
8. Europe and Middle East & Africa Gastrointestinal Testing Panels Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Diagnostic Laboratories
8.3.3. Point-of-Care
8.3.4. Others
8.4. Market Attractiveness Analysis, by End-user
9. Europe and Middle East & Africa Gastrointestinal Testing Panels Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. Europe
9.2.2. Middle East & Africa
9.3. Market Attractiveness Analysis, by Country/Region
10. Europe Gastrointestinal Testing Panels Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Pathogen Type, 2017–2031
10.2.1. Viruses
10.2.2. Bacteria
10.2.3. Parasites
10.3. Market Value Forecast, by Type, 2017–2031
10.3.1. Syndromic Full Multiplex Panel
10.3.2. Low Plex Panel
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Diagnostic Laboratories
10.4.3. Point-of-Care
10.4.4. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. Germany
10.5.1.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.1.1.1. Viruses
10.5.1.1.2. Bacteria
10.5.1.1.3. Parasites
10.5.1.2. Market Value Forecast, by Type, 2017–2031
10.5.1.2.1. Syndromic Full Multiplex Panel
10.5.1.2.2. Low Plex Panel
10.5.1.3. Market Value Forecast, by End-user, 2017–2031
10.5.1.3.1. Hospitals
10.5.1.3.2. Diagnostic Laboratories
10.5.1.3.3. Point-of-Care
10.5.1.3.4. Others
10.5.2. U.K.
10.5.2.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.2.1.1. Viruses
10.5.2.1.2. Bacteria
10.5.2.1.3. Parasites
10.5.2.2. Market Value Forecast, by Type, 2017–2031
10.5.2.2.1. Syndromic Full Multiplex Panel
10.5.2.2.2. Low Plex Panel
10.5.2.3. Market Value Forecast, by End-user, 2017–2031
10.5.2.3.1. Hospitals
10.5.2.3.2. Diagnostic Laboratories
10.5.2.3.3. Point-of-Care
10.5.2.3.4. Others
10.5.3. France
10.5.3.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.3.1.1. Viruses
10.5.3.1.2. Bacteria
10.5.3.1.3. Parasites
10.5.3.2. Market Value Forecast, by Type, 2017–2031
10.5.3.2.1. Syndromic Full Multiplex Panel
10.5.3.2.2. Low Plex Panel
10.5.3.3. Market Value Forecast, by End-user, 2017–2031
10.5.3.3.1. Hospitals
10.5.3.3.2. Diagnostic Laboratories
10.5.3.3.3. Point-of-Care
10.5.3.3.4. Others
10.5.4. Italy
10.5.4.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.4.1.1. Viruses
10.5.4.1.2. Bacteria
10.5.4.1.3. Parasites
10.5.4.2. Market Value Forecast, by Type, 2017–2031
10.5.4.2.1. Syndromic Full Multiplex Panel
10.5.4.2.2. Low Plex Panel
10.5.4.3. Market Value Forecast, by End-user, 2017–2031
10.5.4.3.1. Hospitals
10.5.4.3.2. Diagnostic Laboratories
10.5.4.3.3. Point-of-Care
10.5.4.3.4. Others
10.5.5. Spain
10.5.5.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.5.1.1. Viruses
10.5.5.1.2. Bacteria
10.5.5.1.3. Parasites
10.5.5.2. Market Value Forecast, by Type, 2017–2031
10.5.5.2.1. Syndromic Full Multiplex Panel
10.5.5.2.2. Low Plex Panel
10.5.5.3. Market Value Forecast, by End-user, 2017–2031
10.5.5.3.1. Hospitals
10.5.5.3.2. Diagnostic Laboratories
10.5.5.3.3. Point-of-Care
10.5.5.3.4. Others
10.5.6. Benelux
10.5.6.1.1. Viruses
10.5.6.1.2. Bacteria
10.5.6.1.3. Parasites
10.5.6.2. Market Value Forecast, by Type, 2017–2031
10.5.6.2.1. Syndromic Full Multiplex Panel
10.5.6.2.2. Low Plex Panel
10.5.6.3. Market Value Forecast, by End-user, 2017–2031
10.5.6.3.1. Hospitals
10.5.6.3.2. Diagnostic Laboratories
10.5.6.3.3. Point-of-Care
10.5.6.3.4. Others
10.5.7. Poland
10.5.7.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.7.1.1. Viruses
10.5.7.1.2. Bacteria
10.5.7.1.3. Parasites
10.5.7.2. Market Value Forecast, by Type, 2017–2031
10.5.7.2.1. Syndromic Full Multiplex Panel
10.5.7.2.2. Low Plex panel
10.5.7.3. Market Value Forecast, by End-user, 2017–2031
10.5.7.3.1. Hospitals
10.5.7.3.2. Diagnostic Laboratories
10.5.7.3.3. Point-of-Care
10.5.7.3.4. Others
10.5.8. Norway
10.5.8.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.8.1.1. Viruses
10.5.8.1.2. Bacteria
10.5.8.1.3. Parasites
10.5.8.2. Market Value Forecast, by Type, 2017–2031
10.5.8.2.1. Syndromic Full Multiplex Panel
10.5.8.2.2. Low Plex Panel
10.5.8.3. Market Value Forecast, by End-user, 2017–2031
10.5.8.3.1. Hospitals
10.5.8.3.2. Diagnostic Laboratories
10.5.8.3.3. Point-of-Care
10.5.8.3.4. Others
10.5.9. Sweden
10.5.9.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.9.1.1. Viruses
10.5.9.1.2. Bacteria
10.5.9.1.3. Parasites
10.5.9.2. Market Value Forecast, by Type, 2017–2031
10.5.9.2.1. Syndromic Full Multiplex Panel
10.5.9.2.2. Low Plex Panel
10.5.9.3. Market Value Forecast, by End-user, 2017–2031
10.5.9.3.1. Hospitals
10.5.9.3.2. Diagnostic Laboratories
10.5.9.3.3. Point-of-Care
10.5.9.3.4. Others
10.5.10. Denmark
10.5.10.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.10.1.1. Viruses
10.5.10.1.2. Bacteria
10.5.10.1.3. Parasites
10.5.10.2. Market Value Forecast, by Type, 2017–2031
10.5.10.2.1. Syndromic Full Multiplex Panel
10.5.10.2.2. Low Plex Panel
10.5.10.3. Market Value Forecast, by End-user, 2017–2031
10.5.10.3.1. Hospitals
10.5.10.3.2. Diagnostic Laboratories
10.5.10.3.3. Point-of-Care
10.5.10.3.4. Others
10.5.11. Finland
10.5.11.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.11.1.1. Viruses
10.5.11.1.2. Bacteria
10.5.11.1.3. Parasites
10.5.11.2. Market Value Forecast, by Type, 2017–2031
10.5.11.2.1. Syndromic Full Multiplex Panel
10.5.11.2.2. Low Plex Panel
10.5.11.3. Market Value Forecast, by End-user, 2017–2031
10.5.11.3.1. Hospitals
10.5.11.3.2. Diagnostic Laboratories
10.5.11.3.3. Point-of-Care
10.5.11.3.4. Others
10.5.12. Austria
10.5.12.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.12.1.1. Viruses
10.5.12.1.2. Bacteria
10.5.12.1.3. Parasites
10.5.12.2. Market Value Forecast, by Type, 2017–2031
10.5.12.2.1. Syndromic Full Multiplex Panel
10.5.12.2.2. Low Plex Panel
10.5.12.3. Market Value Forecast, by End-user, 2017–2031
10.5.12.3.1. Hospitals
10.5.12.3.2. Diagnostic Laboratories
10.5.12.3.3. Point-of-Care
10.5.12.3.4. Others
10.5.13. Switzerland
10.5.13.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.13.1.1. Viruses
10.5.13.1.2. Bacteria
10.5.13.1.3. Parasites
10.5.13.2. Market Value Forecast, by Type, 2017–2031
10.5.13.2.1. Syndromic Full Multiplex Panel
10.5.13.2.2. Low Plex Panel
10.5.13.3. Market Value Forecast, by End-user, 2017–2031
10.5.13.3.1. Hospitals
10.5.13.3.2. Diagnostic Laboratories
10.5.13.3.3. Point-of-Care
10.5.13.3.4. Others
10.5.14. Rest of Europe
10.5.14.1. Market Value Forecast, by Pathogen Type, 2017–2031
10.5.14.1.1. Viruses
10.5.14.1.2. Bacteria
10.5.14.1.3. Parasites
10.5.14.2. Market Value Forecast, by Type, 2017–2031
10.5.14.2.1. Syndromic Full Multiplex Panel
10.5.14.2.2. Low Plex Panel
10.5.14.3. Market Value Forecast, by End-user, 2017–2031
10.5.14.3.1. Hospitals
10.5.14.3.2. Diagnostic Laboratories
10.5.14.3.3. Point-of-Care
10.5.14.3.4. Others
10.6. Market Attractiveness Analysis
10.6.1. By Pathogen Type
10.6.2. By Type
10.6.3. By End-user
10.6.4. By Country
11. Middle East & Africa Gastrointestinal Testing Panels Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Pathogen Type, 2017–2031
11.2.1. Viruses
11.2.2. Bacteria
11.2.3. Parasites
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Syndromic Full Multiplex Panel
11.3.2. Low Plex Panel
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Diagnostic Laboratories
11.4.3. Point-of-Care
11.4.4. Others
11.5. Market Value Forecast, by Country, 2017–2031
11.5.1. GCC Countries
11.5.1.1. Market Value Forecast, by Pathogen Type, 2017–2031
11.5.1.1.1. Viruses
11.5.1.1.2. Bacteria
11.5.1.1.3. Parasites
11.5.1.2. Market Value Forecast, by Type, 2017–2031
11.5.1.2.1. Syndromic Full Multiplex Panel
11.5.1.2.2. Low Plex Panel
11.5.1.3. Market Value Forecast, by End-user, 2017–2031
11.5.1.3.1. Hospitals
11.5.1.3.2. Diagnostic Laboratories
11.5.1.3.3. Point-of-Care
11.5.1.3.4. Others
11.5.2. South Africa
11.5.2.1. Market Value Forecast, by Pathogen Type, 2017–2031
11.5.2.1.1. Viruses
11.5.2.1.2. Bacteria
11.5.2.1.3. Parasites
11.5.2.2. Market Value Forecast, by Type, 2017–2031
11.5.2.2.1. Syndromic Full Multiplex Panel
11.5.2.2.2. Low Plex Panel
11.5.2.3. Market Value Forecast, by End-user, 2017–2031
11.5.2.3.1. Hospitals
11.5.2.3.2. Diagnostic Laboratories
11.5.2.3.3. Point-of-Care
11.5.2.3.4. Others
11.5.3. Rest of Middle East & Africa
11.5.3.1. Market Value Forecast, by Pathogen Type, 2017–2031
11.5.3.1.1. Viruses
11.5.3.1.2. Bacteria
11.5.3.1.3. Parasites
11.5.3.2. Market Value Forecast, by Type, 2017–2031
11.5.3.2.1. Syndromic Full Multiplex Panel
11.5.3.2.2. Low Plex Panel
11.5.3.3. Market Value Forecast, by End-user, 2017–2031
11.5.3.3.1. Hospitals
11.5.3.3.2. Diagnostic Laboratories
11.5.3.3.3. Point-of-Care
11.5.3.3.4. Others
11.6. Market Attractiveness Analysis
11.6.1. By Pathogen Type
11.6.2. By Type
11.6.3. By End-user
11.6.4. By Country
12. Competition Landscape
12.1. Company Profiles
12.1.1. Becton, Dickinson and Company (BD)
12.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.1.2. Product Portfolio
12.1.1.3. SWOT Analysis
12.1.1.4. Strategic Overview
12.1.2. bioMérieux SA
12.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.2.2. Product Portfolio
12.1.2.3. SWOT Analysis
12.1.2.4. Strategic Overview
12.1.3. DiaSorin S.p.A (Luminex)
12.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.3.2. Product Portfolio
12.1.3.3. SWOT Analysis
12.1.3.4. Strategic Overview
12.1.4. Quidel Corporation
12.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.4.2. Product Portfolio
12.1.4.3. SWOT Analysis
12.1.4.4. Strategic Overview
12.1.5. QIAGEN
12.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.5.2. Product Portfolio
12.1.5.3. SWOT Analysis
12.1.5.4. Strategic Overview
12.1.6. Seegene, Inc.
12.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.6.2. Product Portfolio
12.1.6.3. SWOT Analysis
12.1.6.4. Strategic Overview
12.1.7. Savyon Diagnostics
12.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.7.2. Product Portfolio
12.1.7.3. SWOT Analysis
12.1.7.4. Strategic Overview
12.1.8. CerTest Biotech S.L.
12.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.8.2. Product Portfolio
12.1.8.3. SWOT Analysis
12.1.8.4. Strategic Overview
12.1.9. Anatolia Geneworks
12.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.9.2. Product Portfolio
12.1.9.3. SWOT Analysis
12.1.9.4. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings